BioSurplus Blog & News

December 29, 2016

Business in Biotech 2016: a Year in Review

While headlines in 2016 were largely dominated by the tumultuous political climate, notable celebrity deaths (RIP Princess Leia), and myriad global crises, there were plenty of scientific developments that caught our attention. An HIV vaccine was cleared for clinical trials, Zika continues to spread, and we finally have images of gravitational waves.

As the year comes to a close, here are five story lines to continue following in 2017.



  1. The Heroes of CRISPR and the CRISPR/Cas-9 patent dispute

Wildpixel, iStock photo, via

The CRISPR/Cas-9 ownership debate is fairly reminiscent of siblings running to their parents for the front seat in a car ride: she called first dibs in the living room, but he got to the driver first. Media attention boomed after Cell published MIT biologist Eric S. Lander’s article The Heroes of CRISPR. Many readers, including Jennifer Doudna of UC Berkeley, disagreed with his depiction of the gene-splicing tool’s history, especially in combination with his Broad Institute affiliation and the ongoing patent battle.

At this point, it’s not a question of whether or not the technology will be patented, but when, and what hurdles or royalty costs researchers outside of the winning institution will face.

  1. EpiPen price hike

    Roel Smart, iStock photo, via

After the Martin Shkreli debacle of 2015, sociopolitical awareness and debate concerning pharmaceutical pricing and ethics is more intense than ever. Under manufacturer Mylan’s ownership, the price of an EpiPen two-pack rose from $267 to $600 in just the past 3 years. Mylan isn’t the only pharmaceutical company raising drug prices, but its lack of competition in both emerging and existing alternatives has drawn criticism for being unethically arbitrary  and disregarding consumer reliance.  Mylan has since released coupons for their injectors and a $300 generic, but it remains to be seen if these efforts have redeemed the company in the eyes of consumers and lawmakers.

For his part, the so-called “Pharma Bro” Shkreli supports Mylan’s pricing, and has expressed willingness to testify in their defense.

  1. Theranos implosion

Jerod harris, TEDMED, via

Theranos’ early fingerstick blood testing device promised to revolutionize diagnostics. Although that may be the case in the future, significant setbacks such as CMS sanctions and CLIA license revocation, critical partnership termination, a criminal investigation, and a 40% workforce reduction rapidly eradicated their credibility and capital. It is still possible that their line of miniLab technology will fulfill the hopes of their micro-testing prototype, but that diagnostics empire will be put on hold.

  1. Recreational marijuana legalization in California and Massachusetts

Jeffrey Thompson, MPR News, via

Although California and Massachusetts aren’t the first states to legalize recreational cannabis, they house three massive biotech clusters, all of which have preliminary entry into the industry due to both states’ long-standing medical marijuana legislation. It is too early to tell exactly how a wider consumer base will affect some of the industry’s existing struggles such as federal regulations, banking, and investor confidence, but startups’ hopes are high (pun intended).

  1. 21st Century Cures Act and the Cancer Moonshot Initiative


The 21st Century Cures Act is bipartisan legislation that allocates training, funds, and awards to biomedical researchers and national institutions, most likely to play out as a rejuvenating shot to academia and innovative startups. In addition to provisions for HHS and CMS, the bill includes increased funds for the NIH and the development of a Capstone Grant program to incentivize and accelerate innovative healthcare.

Additionally, the executive branch recently announced the execution of the Cancer Moonshot Initiative to further oversee and encourage oncology research. Spearheaded by Vice President Joe Biden, the initiative promotes collaboration between the National Cancer Advisory Board and the newly-created Cancer Moonshot Task Force to advocate scientifically-sound ambitions and goals.


Any other biotech news stories from 2016 we should have mentioned? Tell us about it in the comments below!


Want to see more blog posts, equipment updates, and auction news from Biosurplus? Register for our mailing list here!

November 28, 2016

August 15, 2016

WiB Works to Develop Biotech Boardroom Diversity at Liftstream Annual Forum

Women in Bio President Elect Dawn Hocevar will be on hand at the upcoming Liftstream diversity conference in Cambridge, MA to showcase WiB’s Boardroom Ready initiative. The program, which is designed to address the dearth of female members on corporate boards, will utilize the platform of the event to present the first participants and promote the initiative at large. To learn more about  Boardroom Ready, the Liftstream conference, and Women in Bio, click the links below.

July 21, 2016

Auction of Research Assets Begins July 21st

Beginning on July 21, BioSurplus will be conducting a timed online auction of more than 300 lots of research equipment from the labs of XenoPort, Gilead, True North Therapeutics, and more.

This event features a wide range of equipment, including HPLC, FPLC, flow cytometry, and spectrometry systems, as well as centrifuges, cold storage units, glassware, and much more analytical and general benchtop lab equipment.

Many items are available at no reserve price. Please see our auction terms and conditions for more information.

Key Assets Available in this Auction:

  • Applied Biosystems API 4000 Mass Spectrometer With Agilent 1200 Series HPLC and Computer
  • Molecular Devices ImageXpress Ultra Confocal High-Content Analysis System
  • Spectro Ciros CCD
  • Infors Multitron Double-Stack Incubator Shaker
  • Luminex 200 Flow Cytometry System
  • Biotek Synergy 2 Multi-Mode Plate Reader
  • Molecular Devices Flexstation II Plate Reader
  • Amersham / GE Healthcare AKTA FPLC System
  • Varian Prepstar HPLC System
  • Benchtop and Floor Centrifuges from Sorvall, Beckman Coulter, Fisher & more
  • Microscopes from Nikon, VWR, and more
  • Cold storage from Fisher, Nor-Lake & more

Item Viewing Availability

On-site viewings of equipment are available 9AM – 5PM. Item locations may vary between San Diego and South San Francisco.

For more information, call:
Auction Support at 866-236-4496 x222

July 12, 2016

BioSurplus Appoints Bill VanDeWeghe as President and CEO


SAN DIEGO — July 12, 2016 — BioSurplus, America’s preeminent buyer and reseller of preowned lab equipment, announces that its board of directors has appointed Bill VanDeWeghe as president and chief executive officer (CEO). Former president and CEO Cinco Plumb will continue to serve as chairman of the BioSurplus board of directors.

“There are great opportunities ahead for BioSurplus,” says Thor Eakes, a member of the BioSurplus board of directors. “A strong leader, Bill VanDeWeghe has the energy and passion to grow BioSurplus and expand its ability to serve customers. I want to thank Cinco Plumb for his leadership and guidance. For the last 11 years, Cinco has built BioSurplus into a preeminent provider of preowned lab equipment and has set a solid foundation for future growth.”

VanDeWeghe brings over 30 years of management, financial and legal experience to BioSurplus. Previously, he co-founded and served as CEO of RippleNami, Inc., a sophisticated, easy-to-use mapping platform for businesses, NGOs and emergency-management groups. Prior to that, VanDeWeghe served as a managing director at RA Capital Advisors and as a senior shareholder with Klinedinst PC law firm. A former U.S. Army officer, he earned his bachelor’s degree at Princeton University, and his law degree at the Marshall-Wythe School of Law at the College of William and Mary.

“In the biotech and life science industry, BioSurplus has become the ‘go-to’ resource for preowned laboratory equipment,” says Bill VanDeWeghe, president and CEO of BioSurplus. “Whether customers are buying equipment, selling surplus assets or closing entire facilities though our auction capabilities, the BioSurplus brand is synonymous with superb customer service. I am excited to build on this success and lead BioSurplus into the next chapter.”

About BioSurplus

Founded in 2002, BioSurplus is America’s preeminent buyer and reseller of preowned lab equipment. Customers can shop from anywhere using the BioSurplus online store, online auctions or visit us in California in one of our two showrooms. BioSurplus purchases late model working lab instruments from labs that no longer need them, and then passes on the savings of repurposed equipment to its customers. The BioSurplus team is carefully chosen for their scientific experience and background to ensure the proper marketing, selling and handling of a wide range of laboratory instruments. BioSurplus is dedicated to maximizing the value and use of laboratory equipment for both its buying and selling customers.

BioSurplus is headquartered in San Diego and has lab equipment showrooms and warehouses in San Diego and San Francisco. For more information, please visit our website at

July 7, 2016

BioSurplus Donates Microscopes to Local School


BioSurplus is dedicated to supporting the Life Sciences by promoting STEM education for future generations of scientists. Recently, seven compound fluorescence microscopes were donated  to High Bluff Academy in Del Mar, California to be used in their classrooms.

Said Chemistry teacher Sarah Mishek: “BioSurplus has been an incredible asset in helping High Bluff Academy further the development of our STEM program. With the microscopes we received, High Bluff will be able to expand and improve our science curriculum to include a more wide-ranging scope of labs. This donation has greatly contributed to allowing us to teach science through interactive and experiential learning, which we hope will foster a greater love for the sciences and encourage our students to pursue a future in the STEM fields.”

Through this type of outreach, BioSurplus believes we can make a difference.  To learn how BioSurplus can help find the best equipment solution for your lab, contact us at or call 858-550-0800.

June 15, 2016

WIB Promote Boardroom Ready at BIO Convention

boardroomAs an integral part of the Life Science community, BioSurplus is committed to the development of an equal opportunity industry. During the recent Biotechnology Innovation Organization (BIO) convention in San Francisco, BioSurplus National VP of Business Development and Women in Bio President-Elect Dawn Hocevar was on hand to promote the Boardroom Ready program for developing gender diversity in the biotech sector.

With the help of sponsors like LifeSci Advisors and Girls Inc., WIB is working to break systemic inequality and address the lack of women in boardrooms across the industry. By providing a five-day educational program and networking platform, the non-profit is committed to preparing more women for positions at the executive level, as well as aiming to re-educate their male peers about the value women offer when given the same opportunities.

Learn more about WIB and Boardroom Ready here.

May 24, 2016

BioSurplus To Auction Research Equipment from the Laboratories of XenoPort, Inc.

SAN DIEGO—May 24, 2016—BioSurplus, America’s leader in used lab equipment, announced today that it will be holding a timed online auction of lab equipment from XenoPort, Inc.’s discontinued research facility in Northern California. The online auction will run from June 1 through June 8, 2016.

Featuring more than 500 lots of instrumentation, these assets will be auctioned out of BioSurplus’ South San Francisco facility. Available equipment can be viewed during an on-site open house event, which will take place at 111 Kimball Way, South San Francisco 94080 on Tuesday, May 31 from 9 a.m. to 5 p.m.

“This auction presents an exciting opportunity for biotech companies to acquire quality instruments at highly discounted prices,” says Cinco Plumb, President and CEO of BioSurplus.

Items available in this timed online auction include HPLC, LC/MS, flow cytometry and NMR systems, as well as centrifuges, cold storage units, glassware and much more analytical and general benchtop lab equipment.

Please visit  to view the online catalog.

For more information on the auction, please call 866-236-4496, x222, or email

April 15, 2016

Women In Bio Plenary Event at BIO Convention: “The Influential Paths of Great Visionary Leaders”

wiblogoOn Monday, June 6, 2016, BioSurplus will be attending Women In Bio’s annual WIB Plenary Event. This signature event, held in conjunction with the Biotechnology Innovation Organization (BIO) International Convention, will feature a panel of esteemed speakers discussing critical issues affecting women in the life sciences industry.

Speakers include:

  • Firelli Alonso, Senior Director, Biotherapeutics and Vaccines Outsourcing, Pfizer
  • Lisa Cohen, Executive Director, Washington Global Health Alliance
  • Renee Compton Ryan, Vice President, Venture Investments, Johnson & Johnson
  • Bahija Jallal, Executive Vice President, AstraZeneca, Head of MedImmune

As with all WIB events, the Plenary Event will be a fun and congenial atmosphere for networking, bringing together people from all corners of the life sciences industry and spawning new career and business opportunities.

For more information, visit the event page and register today.

April 13, 2016

BioSurplus to Auction Lab Equipment from Vitalea Science

SAN DIEGO, April 13, 2016 — BioSurplus, America’s leader in used lab equipment, will be holding a timed online auction of pharmaceutical R&D equipment from the labs of Vitalea Science in Northern California. The event will run from April 19 to April 26, 2016.

This auction prominently features three Waters Acquity UPLC/UHPLC systems of varying configuration, as well as centrifuges, chest freezers, and other general and benchtop lab equipment.

Items can be viewed on site at BioSurplus South San Francisco from 9AM-5PM.

Please visit to view the online catalog.

For more information on the auction, please call 866-236-4496, x222, or email

image description